First Turn Management LLC Sells 41,280 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

First Turn Management LLC decreased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 37.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 67,942 shares of the company's stock after selling 41,280 shares during the quarter. First Turn Management LLC owned about 0.24% of Krystal Biotech worth $12,367,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Sei Investments Co. grew its holdings in Krystal Biotech by 128.3% in the first quarter. Sei Investments Co. now owns 33,752 shares of the company's stock worth $6,005,000 after purchasing an additional 18,968 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Krystal Biotech by 54.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company's stock worth $117,189,000 after buying an additional 231,255 shares during the period. Shaker Investments LLC OH acquired a new position in Krystal Biotech during the 3rd quarter worth approximately $532,000. Amalgamated Bank boosted its holdings in Krystal Biotech by 937.9% in the second quarter. Amalgamated Bank now owns 7,577 shares of the company's stock worth $1,391,000 after acquiring an additional 6,847 shares in the last quarter. Finally, Everence Capital Management Inc. acquired a new stake in Krystal Biotech in the third quarter valued at approximately $557,000. Institutional investors own 86.29% of the company's stock.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares of the company's stock, valued at $296,814,424.32. This represents a 1.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 14.10% of the company's stock.

Krystal Biotech Stock Performance

NASDAQ:KRYS traded up $2.21 on Tuesday, hitting $177.85. The stock had a trading volume of 215,825 shares, compared to its average volume of 328,296. Krystal Biotech, Inc. has a 1 year low of $99.00 and a 1 year high of $219.34. The firm's fifty day simple moving average is $180.59 and its two-hundred day simple moving average is $181.90. The stock has a market cap of $5.11 billion, a P/E ratio of 99.23 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same period last year, the business posted ($0.67) earnings per share. Krystal Biotech's revenue was up 879.9% on a year-over-year basis. Equities research analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on KRYS shares. Evercore ISI upped their target price on Krystal Biotech from $201.00 to $206.00 and gave the stock an "outperform" rating in a research report on Monday, August 12th. Cantor Fitzgerald restated an "overweight" rating on shares of Krystal Biotech in a report on Thursday, August 29th. William Blair upgraded shares of Krystal Biotech to a "strong-buy" rating in a report on Friday, August 30th. Citigroup upped their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Finally, HC Wainwright reiterated a "buy" rating and set a $221.00 price target on shares of Krystal Biotech in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Krystal Biotech presently has an average rating of "Buy" and an average price target of $197.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).